Latest News and Press Releases

ALK (ALKB:DC / OMX: ALK B / AKBLF): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the...

Company release No. 16/2024 ALK delivers 21% organic revenue growth with an operating profit margin of 19% in Q2 (unaudited) Revenue growth was driven by a continued strong momentum in tablet...

Company release No. 16/2024 ALK delivers 21% organic revenue growth with an operating profit margin of 19% in Q2 (unaudited) Revenue growth was driven by a continued strong momentum in tablet...

ALK (ALKB:DC / OMX: ALK B / AKBLF) har i dag annonceret, at forventningerne til helåret er blevet opjusteret for at reflektere den aktuelle udvikling og udsigterne for resten af året. ...

ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the full-year financial outlook has been upgraded to reflect the current performance and outlook for the remainder of the year. Revenue is...

ALK (ALKB:DC / OMX: ALK B / AKBLF) offentliggør delårsrapport for første halvår (Q2) af 2024 om morgenen fredag den 23. august 2024. ALK afholder senere samme dag kl. 13.30 (CEST) en præsentation...

ALK (ALKB:DC / OMX: ALK B / AKBLF) will publish its results for the first six months (Q2) 2024 in the morning of 23 August 2024. Later same day, the company will host a presentation for investors...

ALK (ALKB:DC / OMX: ALK B / AKBLF) har i dag annonceret, at forventningerne til helåret er blevet opjusteret som følge af bedre end forventet salgsudvikling i andet kvartal og forbedrede udsigter for...

ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the full-year financial outlook has been upgraded to reflect better than expected sales performance in Q2 and an improved outlook for the...

ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that it has decided to withdraw the Biologic License Application (‘BLA’) for its house dust mite (‘HDM’) sublingual allergy immunotherapy tablet in...